Table 1.
Analysis of epitopes recognised by the each anti-fIFN-γ MAb using competitive ELISA and fIFN-γ neutralisation tests.
| Biotinylated anti-fIFN-γ MAb | Neutralisation activity | Epitope | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Noko 1-12.3 | Noko 5-23.1 | Ame 4-12.4 | Noko 3-31.1 | Ame 6-31.1 | Ame 7-19.1 | ||||
| Unlabelled anti-fIFN-γ MAb | Noko 1-12.3 |
*
|
+ | + | + | − | − | − | A |
| Noko 5-23.1 | + |
|
+ | + | − | − | − | A | |
| Ame 4-12.4 | + | + |
|
+ | − | − | − | A | |
| Noko 3-31.1 | + | + | + |
|
76.4 | − | + | B | |
| Ame 6-31.1 | − | − | − | − |
|
+ | + | C | |
| Ame 7-19.1 | − | + | − | 69.8 | + |
|
+ | D | |
*
,+ and − show the percentage of competition more than 80% and less than 20%, respectively.